# Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

> **NCT05118958** · PHASE1 · COMPLETED · sponsor: **KalVista Pharmaceuticals, Ltd.** · enrollment: 37 (actual)

## Conditions studied

- Hereditary Angioedema

## Interventions

- **DRUG:** KVD824 Prototype 1 modified-release tablet
- **DRUG:** KVD824 Prototype 2 modified-release tablet
- **DRUG:** KVD824 Immediate-Release Capsule
- **DRUG:** Placebo to KVD824 Prototype 1
- **DRUG:** KVD824 Prototype 3 modified-release tablet

## Key facts

- **NCT ID:** NCT05118958
- **Lead sponsor:** KalVista Pharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-19
- **Primary completion:** 2020-12-01
- **Final completion:** 2020-12-01
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2021-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05118958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05118958, "Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05118958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*